Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un estudio de TAK-341 en el tratamiento de la atrofia multisistémica

31 de agosto de 2026 actualizado por: Takeda

Un estudio de fase 2 aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia, la seguridad, la tolerabilidad, la farmacocinética y la farmacodinámica de TAK-341 intravenoso en sujetos con atrofia multisistémica

The main aim is to see how TAK-341 works after 52 weeks in participants with multiple system atrophy as measured by the Unified Multiple System Atrophy Rating Scale Part I (UMSARS).

The study will enroll approximately 138 patients. Participants will receive a total of 13 intravenous infusions every 4 weeks approximately, these may be either of TAK-341 or placebo, after each infusion some blood samplings will be taken and other assessments completed.

This trial will be conducted in North America, Europe and Asia.

Descripción general del estudio

Estado

Terminado

Intervención / Tratamiento

Descripción detallada

The drug being tested in this study is called TAK-341. The study will evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of intravenous (IV) TAK-341 in participants with multiple system atrophy (MSA).

The study will enroll approximately 158 participants. The study comprises a screening period of up to 42 days (6 weeks), a 52-week double-blind treatment period, and a follow-up safety visit. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups-which will remain undisclosed to the participant, care provider and investigator during the study:

  • TAK-341
  • Placebo

The change from baseline in UMSARS will be measured at Week 52 post-dose.

This multi-center trial will be conducted worldwide. The duration of treatment in this study will be 52 weeks. Participants will make a follow-up visit to the site after approximately 90 days after the last dose of study treatment.

Tipo de estudio

Intervencionista

Inscripción (Actual)

158

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Berlin, Alemania, 10117
        • Charite - Universitatsmedizin Berlin
    • Bavaria
      • München, Bavaria, Alemania, 81377
        • Klinikum Groshadern, LMU
    • Hesse
      • Kassel, Hesse, Alemania, 34128
        • Paracelsus-Elena-Klinik Kassel
    • Lower Saxony
      • Hanover, Lower Saxony, Alemania, 30625
        • Medizinische Hochschule Hannover
    • North Rhine-Westphalia
      • Bochum, North Rhine-Westphalia, Alemania, 44791
        • Universitaetsklinikum der Ruhr-Universitaet Bochum (UKRUB) - St. Josef-Hospital
      • Bonn, North Rhine-Westphalia, Alemania, 53127
        • Deutsches Zentrum fur Neurodegenerative Erkrankung
      • Münster, North Rhine-Westphalia, Alemania, 48149
        • Universitatsklinikum Munster
    • Saxony
      • Dresden, Saxony, Alemania, 01307
        • Universitatsklinikum Carl Gustav Carus an der TU Dresden
      • Leipzig, Saxony, Alemania, 04103
        • Universitatsklinikum Leipzig
    • Styria
      • Graz, Styria, Austria, 8036
        • Medizinische Universitat Graz
      • Aarhus N, Dinamarca, 8200
        • Aarhus Universitetshospital
    • Capital
      • København NV, Capital, Dinamarca, 2400
        • Bispebjerg Hospital
      • Barcelona, España, 08035
        • Hospital Universitario Vall d'Hebron
      • Barcelona, España, 08041
        • Hospital de La Santa Creu i Sant Pau
      • Madrid, España, 28034
        • Hospital Universitario Ramon y Cajal
      • Madrid, España, 28006
        • Hospital Universitario de La Princesa
      • Valencia, España, 46026
        • Hospital Universitari i Politecnic La Fe de Valencia
    • Vizcaya
      • Barakaldo, Vizcaya, España, 48903
        • Hospital Universitario Cruces
    • Michigan
      • Farmington Hills, Michigan, Estados Unidos, 48025
        • Quest Research Institute - Alcanza - HyperCore
    • Minnesota
      • Rochester, Minnesota, Estados Unidos, 55905-0001
        • Mayo Clinic
    • New York
      • New York, New York, Estados Unidos, 10016-6402
        • NYU Langone Health
    • North Carolina
      • Durham, North Carolina, Estados Unidos, 27705-4410
        • Duke University School of Medicine
    • Ohio
      • Cleveland, Ohio, Estados Unidos, 44195
        • The Cleveland Clinic Foundation
    • Texas
      • Dallas, Texas, Estados Unidos, 75390-7208
        • University of Texas Southwestern Medical Center
    • Washington
      • Spokane, Washington, Estados Unidos, 99202-1342
        • Inland Northwest Research
    • Bouches-du-Rhone
      • Marseille, Bouches-du-Rhone, Francia, 13385
        • Hopitaux de La Timone
      • Salerno, Italia, 84131
        • Azienda Ospedaliera Universitaria OO.RR. San Giovanni di Dio Ruggi dAragona
    • Lazio
      • Rome, Lazio, Italia, 00163
        • IRCCS San Raffaele Roma
    • Lombardy
      • Milan, Lombardy, Italia, 20133
        • Fondazione IRCCS Di Rilievo Nazionale Istituto Nazionale Neurologico Carlo Besta
      • Milan, Lombardy, Italia, 20122
        • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
      • Rozzano, Lombardy, Italia, 20089
        • Istituto Clinico Humanitas
    • Veneto
      • Padova, Veneto, Italia, 35126
        • Azienda Ospedale Universita Padova
    • Chiba
      • Chuo-ku, Chiba, Japón, 260-8677
        • Chiba University Hospital
    • Hokkaido
      • Sapporo, Hokkaido, Japón, 060-8638
        • Hokkaido University Hospital
    • Kyoto
      • Kyoto, Kyoto, Japón, 606-8507
        • Kyoto University Hospital
    • Tokyo
      • Bunkyo-Ku, Tokyo, Japón, 113-0033
        • The University of Tokyo Hospital
      • Bunkyo-Ku, Tokyo, Japón, 113-8519
        • Medical Hospital of Tokyo Medical and Dental University
      • Kodaira-Shi, Tokyo, Japón, 187-8551
        • National Center of Neurology and Psychiatry
    • Lisbon District
      • Loures, Lisbon District, Portugal, 2674-514
        • Campus Neurologico Senior
    • Porto District
      • Senhora da Hora, Porto District, Portugal, 4464-513
        • Hospital Pedro Hispano
    • Hampshire
      • Southampton, Hampshire, Reino Unido, SO16 6YD
        • Southampton General Hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

40 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion criteria:

Diagnostic:

  1. The participant has a diagnosis of possible or probable MSA using the modified Gilman et al, 2008 diagnostic criteria.
  2. The participant's onset of first MSA symptoms occurred ≤4 years before screening, as assessed by the investigator.
  3. Evidence of MSA specific symptoms and deficits as measured by the UMSARS scale.

Exclusion criteria:

Medical History:

1. The participant has any contraindication to study procedures.

Diagnostic Assessments:

  1. Presence of confounding diagnosis and/or conditions that could affect participant's safety during the study per investigator judgement.
  2. The participant's participation in a previous study of a disease-modifying therapy (with proven receipt of active treatment) will compromise the interpretability of the data from the present study, per consultation with medical monitor or designee.

Other:

1. The participant has participated in another study investigating active or passive immunization against α-synuclein (αSYN) for progressive disease (PD) or MSA, or has had immunoglobulin G therapy, within 6 months before screening.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Triple

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador de placebos: Placebo

Participants received TAK-341 matching placebo intravenous (IV) infusions, once every 4 weeks (Q4W) for 52 weeks.

TAK-341-matching placebo IV infusion

Experimental: TAK-341

Participants received TAK-341, IV Q4W for 52 weeks. An early set of participants initially received 2400 milligrams (mg) to determine pharmacokinetic (PK) parameters. Following the early participants, a dose of 2000 mg was given until the data from the PK participants became available. All participants then received 2400 mg until the end of treatment at 52 weeks.

TAK-341 IV infusion

Otros nombres:
  • MEDI1341

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change From Baseline in Modified Unified Multiple System Atrophy Rating Scale (UMSARS) Part I Total Score at Week 52
Periodo de tiempo: Baseline, Week 52

UMSARS Part I (historical review) is a 12-item scale that was adapted from the Unified Parkinson's Disease Rating Scale (UPDRS) and is used to assess activities related to motor disability and autonomic dysfunction. In this study, the UMSARS was modified to exclude the sexual function item. Thus, total 11 items were assessed. Each item was initially scored on a scale from 0 (normal) to 4 (severe); ratings of normal (0) and mild (1) were then combined and recorded as 0, making minimum score 0 and maximum score 3. The investigator rated the average functional situation for the past 2 weeks according to findings from the participant and caregiver interview and indicated the score that best fit with the participant's status. The total score is a sum of scores from all domains and range from 0 to 33. Higher scores indicate worse impairment.

Baseline, Week 52

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Number of Participants With Anti-Drug Antibodies
Periodo de tiempo: Up to Week 61
Up to Week 61
Change From Baseline in 11-item UMSARS at Week 52
Periodo de tiempo: Baseline, Week 52

The 11- item UMSARS includes 11 items from Part I and II to assess both motor and autonomic disability. UMSARS Part I (historical review) is used to assess activities related to motor disability and autonomic dysfunction. UMSARS Part II (motor examination) is used to measure the functional impairment and specific parkinsonian or cerebellar features. Each item was scored on a scale from 0 (normal) to 4 (severe); total score ranges from 0 to 44, higher scores indicated worse impairment.

Baseline, Week 52
Change From Baseline in the UMSARS Total Score (UMSARS Part I + Part II) at Week 52
Periodo de tiempo: Baseline, Week 52

UMSARS total scale consists of all items from UMSARS Parts I and II. UMSARS Part I (historical review): 12-item scale used to assess activities related to motor disability and autonomic dysfunction. Each item is scored from 0 (normal) to 4 (severe). UMSARS Part II (motor examination): 14-item scale used to measure the functional impairment (for example speech, rapid alternating movements of the hands, finger taps, leg agility) of selected complex movements, and specific parkinsonian (tremor at rest) or cerebellar (ocular motor dysfunction, heel-shin test) features. The worst affected limb was assessed, and each item was scored from 0 (normal) to 4 (severe). UMSARS Part I and Part II total score is the sum of UMSARS Part I and Part II and ranges from 0 to 104. A higher score indicates worse impairment.

Baseline, Week 52
Change From Baseline in UMSARS Part I 11-Item Score at Week 52
Periodo de tiempo: Baseline, Week 52

UMSARS Part I (historical review) is a 12-item scale that was adapted from the UPDRS. In this study, the UMSARS was modified to exclude the sexual function item. The UMSARS is used to assess activities related to motor disability and autonomic dysfunction. Each item was scored on a scale from 0 (normal) to 4 (severe). UMSARS Part I 11-item total score is the total score of UMSARS Part I, excluding the sexual function item, and without collapse of ratings of scale items. The UMSARS Part I 11-item total score ranges from 0 to 44, and higher scores indicate worse impairment.

Baseline, Week 52
Change From Baseline in UMSARS Part II at Week 52
Periodo de tiempo: Baseline, Week 52

UMSARS Part II (motor examination): 14-item scale used to measure the functional impairment (e.g., speech, rapid alternating movements of the hands, finger taps, leg agility) of selected complex movements, and specific parkinsonian (tremor at rest) or cerebellar (ocular motor dysfunction, heel-shin test) features. the worst affected limb was assessed, and each item was scored from 0 (normal) to 4 (severe). The UMSARS Part II total score ranges from 0 to 56, and higher scores indicate worse impairment.

Baseline, Week 52
Change From Baseline on Clinical Global Impression-Severity (CGI-S) Score
Periodo de tiempo: Baseline, Week 24 and Week 52

The CGI-S is used to assess the clinician's impression of the participant's clinical condition. The clinician rates the current severity of the participant's illness on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (most extremely ill). The rating was based on observed and reported symptoms, behaviour, and function and reflected the severity level at the time of the assessment. A higher score indicates worse impairment.

Baseline, Week 24 and Week 52
Change From Baseline in Scales for Outcomes in Parkinson's Disease - Autonomic Dysfunction (SCOPA-AUT) Total Score
Periodo de tiempo: Baseline, Week 24 and Week 52

The SCOPA-AUT is a participant-reported outcome that assesses autonomic function. Autonomic function is a critical symptom domain for MSA. The scale was completed by participants and consisted of 25 items assessing the following domains: gastrointestinal (7 items), urinary (6 items), cardiovascular (3 items), thermoregulatory (4 items), pupillomotor (1 item), and sexual (2 items for men and 2 items for women). The score for each item ranged from 0 (never experiencing the symptom) to 3 (often experiencing the symptom). The total composite score including all domains was reported. The score range was 0 (no symptoms) to 69 (highest burden of symptoms). A higher score indicates worse impairment.

Baseline, Week 24 and Week 52
Overall Survival (OS) at Week 52
Periodo de tiempo: At Week 52

OS was estimated with Kaplan-Meier survival estimates, along with 95% confidence interval. A cox proportional hazards model was fitted to model the survival probability with treatment as the predictor. The participants with missing value were censored. The probabilities of survival at Week 52 for participants were estimated and reported.

At Week 52
Change From Baseline in Cerebrospinal Fluid (CSF) Free Alpha-Synuclein (αSYN)
Periodo de tiempo: Baseline, Week 52

α-Synucleinopathies are diseases characterized by abnormal accumulation of aggregated αSYN. In participants with MSA, αSYN is seen to accumulate primarily in oligodendrocytes, forming glial cytoplasmic inclusions. A negative change from Baseline indicates an improvement.

Baseline, Week 52
Maximum Observed Steady State Serum Concentration (Cmax) for TAK-341
Periodo de tiempo: On Day 57- immediately before end of infusion (EOI) (60 minutes), 6 hours and 24 hours.

Cmax is the maximum observed serum concentration for TAK-341.

On Day 57- immediately before end of infusion (EOI) (60 minutes), 6 hours and 24 hours.
Time to Maximum Steady State Concentration (Tmax) for TAK-341
Periodo de tiempo: On Day 57- immediately before EOI (60 minutes), 6 hours and 24 hours.

Tmax is the time of first occurrence of maximum observed concentration for TAK-341.

On Day 57- immediately before EOI (60 minutes), 6 hours and 24 hours.
Area Under the Serum Concentration Time Curve (AUCτ) at Steady State for TAK-341
Periodo de tiempo: On Day 57- immediately before EOI (60 minutes), 6 hours and 24 hours.

AUCτ is the area under the serum concentration-time curve during a dosing interval.

On Day 57- immediately before EOI (60 minutes), 6 hours and 24 hours.
CSF Concentration of TAK-341
Periodo de tiempo: On Day 1, Day 85 and Day 365

Lumbar puncture was performed for CSF on Day 1, Day 85 and Day 365, predose.

On Day 1, Day 85 and Day 365
Number of Participants With at Least One Adverse Event (AE)
Periodo de tiempo: Up to Week 61

An adverse event (AE) is defined as any untoward medical occurrence in a participant administered a pharmaceutical product; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an adverse event that occurs after administration of the first dose of study treatment and up through 90 days after the last dose of study treatment.

Up to Week 61

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Investigadores

  • Director de estudio: Medical Director, Takeda (Note: This product was divested to Alexion/AstraZeneca in 2026)

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

16 de noviembre de 2022

Finalización primaria (Actual)

28 de julio de 2025

Finalización del estudio (Actual)

28 de julio de 2025

Fechas de registro del estudio

Enviado por primera vez

1 de septiembre de 2022

Primero enviado que cumplió con los criterios de control de calidad

1 de septiembre de 2022

Publicado por primera vez (Actual)

2 de septiembre de 2022

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

24 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

31 de agosto de 2026

Última verificación

1 de agosto de 2026

Más información

Términos relacionados con este estudio

Palabras clave

Otros números de identificación del estudio

  • TAK-341-2001
  • 2022-000336-28 (Número EudraCT)
  • jRCT2011220029 (Identificador de registro: jRCT)
  • 2023-509876-40-00 (Ctis)
  • 2023 (Subvención/contrato del NIH de EE. UU.)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

De-identified individual participant data from this particular study will not be shared as the data are subject to contractual (or consent) provisions that prohibit transfer to third parties.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

Sí

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir